GlassScriptPhysician profile
Ryan Errol Jennings
NPI 1396959805
$1,863.82
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $623 · 2023: $836 · 2024: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,240.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $519.67 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $186.98 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $182.99 | 2022-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $180.30 | 2022-2024 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $172.97 | 2022-2024 | Freestyle Libre 3, Eterna |
| Pfizer INC. | $157.88 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $115.68 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.21 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.91 | 2022-2024 | Xifaxan, Trulance |
| Exact Sciences Corporation | $29.84 | 2023 | Cologuard Collection Kit |
| Nevro Corp. | $29.12 | 2022 | |
| Mylan Specialty L.P. | $26.10 | 2023 | Yupelri |
| Xeris Pharmaceuticals, INC. | $19.97 | 2022 | |
| Currax Pharmaceuticals LLC | $17.95 | 2023 | Contrave |
| Glaxosmithkline, LLC. | $17.22 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $15.69 | 2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $13.40 | 2024 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Jennings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.